Null Results in Brief Genetic Variations in XRCC2 and XRCC3 Are Not Associated with Endometrial Cancer Risk

Results We observed no overall associations of the four genotypes with endometrial cancer risk (Tables 1 and 2). We observed that, compared with the XRCC2 31479 G/G genotype, the multivariate ORs for the G/A and A/A genotypes were 0.95 (95% CI, 0.58 –1.54) and 2.05 (95% CI, 0.24 –17.82), respectively. Three common haplotypes in XRCC3 accounted for 99% of chromosomes in the present study population. As compared with women who were homozygous for XRCC3 4541A, women who were heterozygous for 4541G allele had a multivariate risk of 1.00 (95% CI, 0.69 –1.43), and women who were homozygous for 4541G allele had a multivariate risk of 0.75 (95% CI, 0.30 –1.87). As compared with noncarriers, the multivariate ORs for women with one XRCC3 17893G allele and two alleles were 0.95 (95% CI, 0.66 – 1.36) and 0.69 (95% CI, 0.39 –1.21), respectively, with an OR of 0.89 (95% CI, 0.63–1.25) for carriage of at least one G allele. As compared with women with 18067 C/C genotype, women with C/T and T/T genotypes had multivariate OR of 1.03 (95% CI, 0.72–1.47) and 1.15 (95% CI, 0.67– 1.98), respectively. No significant interactions were observed between these polymorphisms and risk factors such as body mass index, weight gain, and smoking (pack-years).